|
|
 Previous Article | Table of Contents | Next Article 
Blood, 15 November 2000, Vol. 96, No. 10, pp. 3637-3643
TRANSPLANTATION
Limited engraftment capacity of bone marrow-derived mesenchymal
cells following T-cell-depleted hematopoietic stem cell
transplantation
Daniela Cilloni,
Carmelo Carlo-Stella,
Franca Falzetti,
Gabriella Sammarelli,
Ester Regazzi,
Simona Colla,
Vittorio Rizzoli,
Franco Aversa,
Massimo F. Martelli, and
Antonio Tabilio
From the Department of Hematology, University
of Parma, Parma, Italy; the Department of Internal Medicine, University
of Torino, Torino, Italy; and the Department of Hematology, University
of Perugia, Perugia, Italy.
The engraftment capacity of bone marrow-derived mesenchymal
cells was investigated in 41 patients who had received a
sex-mismatched, T-cell-depleted allograft from human leukocyte antigen
(HLA)-matched or -mismatched family donors. Polymerase chain reaction
(PCR) analysis of the human androgen receptor (HUMARA) or the
amelogenin genes was used to detect donor-derived mesenchymal cells.
Only 14 marrow samples (34%) from 41 consenting patients generated a
marrow stromal layer adequate for PCR analysis. Monocyte-macrophage contamination of marrow stromal layers was reduced below the
levels of sensitivity of HUMARA and amelogenin assays (5% and
3%, respectively) by repeated trypsinizations and treatment with the
leucyl-leucine (leu-leu) methyl ester. Patients who received allografts
from 12 female donors were analyzed by means of the HUMARA assay, and in 5 of 12 cases a partial female origin of stromal cells was demonstrated. Two patients who received allografts from male donors were analyzed by amplifying the amelogenin gene, and in both cases a
partial male origin of stromal cells was shown. Fluorescent in situ
hybridization analysis using a Y probe confirmed the results of PCR
analysis and demonstrated in 2 cases the existence of a mixed
chimerism at the stromal cell level. There was no statistical difference detected between the dose of fibroblast progenitors (colony-forming unit-F [CFU-F]) infused to patients with
donor- or host-derived stromal cells
(1.18 ± 0.13 × 104/kg vs
1.19 ± 0.19 × 104/kg; P  .97).
In conclusion, marrow stromal progenitors reinfused in patients
receiving a T-cell-depleted allograft have a limited capacity of
reconstituting marrow mesenchymal cells.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
K. Tomiyama, N. Murase, D. B. Stolz, H. Toyokawa, D. R. O'Donnell, D. M. Smith, J. R. Dudas, J. P. Rubin, and K. G. Marra
Characterization of Transplanted Green Fluorescent Protein+ Bone Marrow Cells into Adipose Tissue
Stem Cells,
February 1, 2008;
26(2):
330 - 338.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Shi, J. Li, L. Liao, B. Chen, B. Li, L. Chen, H. Jia, and R. C. Zhao
Regulation of CXCR4 expression in human mesenchymal stem cells by cytokine treatment: role in homing efficiency in NOD/SCID mice
Haematologica,
July 1, 2007;
92(7):
897 - 904.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. De Becker, P. Van Hummelen, M. Bakkus, I. Vande Broek, J. De Wever, M. De Waele, and I. Van Riet
Migration of culture-expanded human mesenchymal stem cells through bone marrow endothelium is regulated by matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-3
Haematologica,
April 1, 2007;
92(4):
440 - 449.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Ogawa, A. C. LaRue, and C. J. Drake
Hematopoietic origin of fibroblasts/myofibroblasts: its pathophysiologic implications
Blood,
November 1, 2006;
108(9):
2893 - 2896.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. Huang, V. La Russa, A. Alzoubi, and P. Schwarzenberger
Interleukin-17A: A T-Cell-Derived Growth Factor for Murine and Human Mesenchymal Stem Cells
Stem Cells,
June 1, 2006;
24(6):
1512 - 1518.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
V. Sordi, M. L. Malosio, F. Marchesi, A. Mercalli, R. Melzi, T. Giordano, N. Belmonte, G. Ferrari, B. E. Leone, F. Bertuzzi, et al.
Bone marrow mesenchymal stem cells express a restricted set of functionally active chemokine receptors capable of promoting migration to pancreatic islets
Blood,
July 15, 2005;
106(2):
419 - 427.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Djouad, P. Plence, C. Bony, P. Tropel, F. Apparailly, J. Sany, D. Noel, and C. Jorgensen
Immunosuppressive effect of mesenchymal stem cells favors tumor growth in allogeneic animals
Blood,
November 15, 2003;
102(10):
3837 - 3844.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Cancedda, G. Bianchi, A. Derubeis, and R. Quarto
Cell Therapy for Bone Disease: A Review of Current Status
Stem Cells,
September 1, 2003;
21(5):
610 - 619.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. M. Caplice, T. J. Bunch, P. G. Stalboerger, S. Wang, D. Simper, D. V. Miller, S. J. Russell, M. R. Litzow, and W. D. Edwards
Smooth muscle cells in human coronary atherosclerosis can originate from cells administered at marrow transplantation
PNAS,
April 15, 2003;
100(8):
4754 - 4759.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Di Nicola, C. Carlo-Stella, M. Magni, M. Milanesi, P. D. Longoni, P. Matteucci, S. Grisanti, and A. M. Gianni
Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli
Blood,
May 15, 2002;
99(10):
3838 - 3843.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
